Physician profile
Ravin Garg
NPI 1043385180
$10,047.59
in general payments reported to CMS, 2019-2025
36 companies · $219 in 2025
The $219 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,065 · 2020: $1,059 · 2021: $45.50 · 2022: $2,301 · 2023: $3,168 · 2024: $190 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Food and Beverage: $577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Food and Beverage | $576.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $3,070.42 | 2019-2024 | Welireg, Keytruda, Reblozyl |
| Genzyme Corporation | $2,446.50 | 2019 | |
| Daiichi Sankyo INC. | $2,000.00 | 2022 | |
| Rigel Pharmaceuticals, INC. | $1,000.00 | 2020 | |
| Alexion Pharmaceuticals, INC. | $251.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $131.51 | 2019-2025 | |
| Janssen Biotech, INC. | $122.65 | 2019-2025 | Tecvayli |
| Abbvie INC. | $108.23 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $105.57 | 2022-2023 | Imbruvica, Epkinly |
| Celgene Corporation | $77.43 | 2019-2024 | Reblozyl |
| Pfizer INC. | $71.27 | 2019-2024 | |
| Astellas Pharma US INC | $51.32 | 2019-2025 | Padcev |
| Glaxosmithkline, LLC. | $51.30 | 2021-2024 | Jemperli, Zejula |
| Argon Medical Devices, INC. | $50.47 | 2023 | Cleaner |
| Janssen Pharmaceuticals, INC | $38.65 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $36.48 | 2019 | |
| Invivyd INC | $35.07 | 2024 | Pemgarda |
| Amgen INC. | $34.48 | 2019-2023 | Blincyto, Kyprolis |
| Azurity Pharmaceuticals, INC. | $31.88 | 2025 | Danziten |
| Emd Serono, INC. | $28.82 | 2019 | |
| Lilly USA, LLC | $28.73 | 2019 | |
| Incyte Corporation | $27.54 | 2019-2020 | |
| Gilead Sciences, INC. | $26.15 | 2019-2021 | |
| Coherus Oncology, INC. | $25.88 | 2025 | Loqtorzi |
| Astrazeneca Pharmaceuticals LP | $23.47 | 2019 | |
| Shire North American Group INC | $22.76 | 2019 | |
| Jazz Pharmaceuticals INC. | $19.49 | 2025 | |
| Tesaro, INC. | $17.71 | 2019 | |
| Dendreon Pharmaceuticals LLC | $16.36 | 2019 | |
| Alnylam Pharmaceuticals INC. | $16.29 | 2025 | Givlaari |
| Seagen INC. | $14.81 | 2019 | |
| Array Biopharma INC | $13.75 | 2019 | |
| Genentech USA, INC. | $13.54 | 2019 | |
| Puma Biotechnology, INC. | $13.40 | 2020 | |
| Heron Therapeutics, INC. | $12.96 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravin Garg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.